Skip to main content
Effective Health Care Program

Comparative Effectiveness of Lipid-Modifying Agents

Systematic Review Archived

Archived: This report has been updated.


People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Excerpt

This evidence report was commissioned by the Agency for Healthcare Research and Quality (AHRQ) to address the following key questions: Key Question 1. For patients who require intensive lipid-modifying therapy, what are the comparative long-term benefits and rates of serious adverse events of coadministration of different lipid-modifying agents (i.e., a statin plus another lipid-modifying agent) compared with higher dose statin monotherapy? Key Question 2. Do these regimens differ in reaching LDL targets (or other surrogate markers), short-term side effects, tolerability, and/or adherence? Key Question 3. Compared with higher dose statins and to one another, do combination regimens differ in benefits and harms within subgroups of patients?